Device-based Therapies for Resistant Hypertension

Author(s): Rosa Maria Bruno, Alessia Di Giulio, Giampaolo Bernini, Agostino Virdis, Lorenzo Ghiadoni, Stefano Taddei

Journal Name: Current Pharmaceutical Design

Volume 19 , Issue 13 , 2013

Become EABM
Become Reviewer
Call for Editor


Hypertension is universally considered the most detrimental among cardiovascular risk factors. Despite the overwhelming evidence of benefits deriving from lowering blood pressure, its control among the hypertensive population is still unsatisfactory. Resistant hypertension has a non negligible prevalence among hypertensive patients, and it is associated with a worse cardiovascular prognosis. There is need of new therapeutic approaches for reducing cardiovascular risk in this population.

Sympathetic nervous system is known to play a major role in development and maintenance of essential hypertension, thus in the past decades several efforts have been made to counteract its overactivation. Novel non-pharmacological, promising approaches targeting sympathetic nervous system are now available, such as renal denervation and baroceptor-activating therapy. This review is aimed at describing essential clinical aspects of resistant hypertension, physiopatological basis of autonomic modulation as a target for hypertension treatment, and the available clinical evidence about efficacy and safety of device-based therapies for resistant hypertension. Present limitations and future perspectives were also considered.

Keywords: Resistant hypertension, Sympathetic nervous system, renal denervation, baroceptor-activating therapy, cardiovascular risk factors, blood pressure, prognosis, autonomic modulation, clinical evidence, device-based therapies

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Published on: 28 February, 2013
Page: [2401 - 2408]
Pages: 8
DOI: 10.2174/1381612811319130008
Price: $65

Article Metrics

PDF: 13